文献速递慢性肾脏病肾小球疾病

利拉鲁肽在2型糖尿病合并慢性肾脏病患者中的安全性

Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-03-04

LEADER试验的事后分析评估利拉鲁肽在合并CKD的2型糖尿病患者中的安全性。共9340例患者随机接受利拉鲁肽或安慰剂,其中2158例合并CKD。结果显示,CKD患者严重不良事件更常见,但利拉鲁肽与安慰剂组间无差异,且利拉鲁肽显著降低CKD或白蛋白尿患者的严重低血糖风险。

要点

  • 合并CKD的2型糖尿病患者使用利拉鲁肽总体安全,不良事件与安慰剂相当。
  • 利拉鲁肽显著降低CKD患者严重低血糖风险(HR 0.63)。
  • 利拉鲁肽显著降低微量或大量白蛋白尿患者严重低血糖风险(HR 0.57)。

核心结论

  • 在LEADER试验中,利拉鲁肽用于合并CKD的2型糖尿病患者是安全的,且CKD与非CKD患者间无差异。

研究设计与样本

  • LEADER试验的事后分析,9340例2型糖尿病患者随机接受利拉鲁肽或安慰剂,其中2158例合并CKD(eGFR<60 ml/min per 1.73 m2)。

主要发现

  • CKD患者严重不良事件发生率高于非CKD患者(59% vs 50%;交互P=0.11),但利拉鲁肽与安慰剂组间发生程度相同。
  • 在微量或大量白蛋白尿患者中,未观察到不良事件与随机治疗的交互作用(交互P=0.11)。
  • 利拉鲁肽较安慰剂显著降低CKD患者严重低血糖风险(HR 0.63,95% CI 0.43-0.91)。
  • 利拉鲁肽较安慰剂显著降低微量或大量白蛋白尿患者严重低血糖风险(HR 0.57,95% CI 0.40-0.82)。

关键数值与推荐

  • CKD定义为eGFR<60 ml/min per 1.73 m2,非CKD为eGFR≥60 ml/min per 1.73 m2。
  • 大量白蛋白尿定义为尿白蛋白-肌酐比值>300 mg/g,微量白蛋白尿定义为≥30至≤300 mg/g。
  • CKD患者基线平均eGFR为46±11 ml/min per 1.73 m2,非CKD患者为91±22 ml/min per 1.73 m2。

临床怎么用

  • 对于合并CKD的2型糖尿病患者,利拉鲁肽可安全使用,且可能降低严重低血糖风险。

局限性

  • 本研究为LEADER试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER. Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care. Of those, 2158 patients had CKD versus 7182 without CKD (defined as eGFR <60 versus ≥60 ml/min per 1.73 m2, respectively); 966 patients had macroalbuminuria and 2456 had microalbuminuria (urine albumin-creatinine ratio >300 mg/g and ≥30 to ≤300 mg/g, respectively). At baseline, the mean eGFR in patients with CKD was 46±11 ml/min per 1.73 m2 versus 91±22 ml/min per 1.73 m2 in those without CKD. Time to first event within event groups was analyzed using Cox regression with treatment group, baseline eGFR group, or baseline albuminuria group as fixed factors. RESULTS: Overall, serious adverse events were more frequently recorded in patients with CKD compared with those without CKD (59% versus 50%; interaction P=0.11); however, they occurred to the same extent in those on liraglutide versus placebo. Similarly, no interaction of adverse events with randomized therapy was observed in patients with micro- or macro- versus normoalbuminuria (interaction P=0.11). Risk of severe hypoglycemia was significantly reduced with liraglutide versus placebo in patients with CKD or with micro- or macroalbuminuria (hazard ratio, 0.63 [95% CI, 0.43 to 0.91] and 0.57 [95% CI, 0.40 to 0.82], respectively). CONCLUSIONS: In LEADER, the use of liraglutide in those with CKD was safe, with no difference between patients with and without CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov; NCT01179048 (https://clinicaltrials.gov/ct2/show/NCT01179048).

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mann JFE, Fonseca VA, Poulter NR, et al. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020. PMID: 32132141. doi:10.2215/CJN.11881019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。